Suppr超能文献

HDAC10与非小细胞肺癌患者的PD-L1表达及不良预后呈正相关。

HDAC10 Is Positively Associated With PD-L1 Expression and Poor Prognosis in Patients With NSCLC.

作者信息

Liu Xiaomei, Wang Yuxi, Zhang Rong, Jin Ting, Qu Liangliang, Jin Qianwen, Zheng Jiasu, Sun Jiaqi, Wu Ziqing, Wang Linxi, Liu Tianxu, Zhang Yinxu, Meng Xiao, Wang Ying, Wei Ning

机构信息

Department of Oncology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China.

Department of Medicine, Jinzhou Medical University, Jinzhou, China.

出版信息

Front Oncol. 2020 Apr 21;10:485. doi: 10.3389/fonc.2020.00485. eCollection 2020.

Abstract

Currently, non-small cell lung carcinoma (NSCLC) is a major worldwide health problem. Meanwhile accumulating evidence indicates that histone deacetylase (HDAC) activation could induce PD-L1 expression in various types of cancer, especially in myeloma and B-cell lymphomas. Therefore, we hypothesized that high-level expression of HDAC10 is associated with PD-L1 induction and poor prognosis in patients with NSCLC. In total 180 NSCLC patients receiving complete pulmonary resection and systematic lymph node dissection were enrolled from April 2004 to August 2009. The patients with integrated clinicopathological records were followed up. The expression level of HDAC10 and PD-L1 in tissue samples was determined by immunohistochemistry. We observed that HDAC10 expression in lung cancer tissue is significantly higher than that in corresponding para-cancer tissue. Moreover, HDAC10 expression positively correlated with the expression level of PD-L1 ( = 0.213, < 0.05) in NSCLC patients. Subgroup, multivariate analysis showed that the expression level of HDAC10 can be an independent prognostic factor and high-level expression of HDAC10 indicated poor overall survival for pulmonary carcinoma ( = 0.540, < 0.001). Our findings suggest that the expression level of HDAC10 is positively associated with PD-L1 expression and may predict the outcome of patients with NSCLC.

摘要

目前,非小细胞肺癌(NSCLC)是一个全球性的主要健康问题。与此同时,越来越多的证据表明,组蛋白去乙酰化酶(HDAC)激活可诱导多种类型癌症中程序性死亡受体配体1(PD-L1)的表达,尤其是在骨髓瘤和B细胞淋巴瘤中。因此,我们推测HDAC10的高表达与NSCLC患者的PD-L1诱导及预后不良有关。2004年4月至2009年8月,共纳入180例接受了全肺切除及系统性淋巴结清扫的NSCLC患者。对具有完整临床病理记录的患者进行随访。通过免疫组织化学法测定组织样本中HDAC10和PD-L1的表达水平。我们观察到肺癌组织中HDAC10的表达明显高于相应癌旁组织。此外,在NSCLC患者中,HDAC10表达与PD-L1表达水平呈正相关( = 0.213, < 0.05)。亚组多因素分析显示,HDAC10表达水平可作为独立的预后因素,HDAC10高表达提示肺癌患者总生存期较差( = 0.540, < 0.001)。我们的研究结果表明,HDAC10表达水平与PD-L1表达呈正相关,可能预测NSCLC患者的预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b09/7186423/c01cb75041a5/fonc-10-00485-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验